These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 18186499

  • 1. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E, Kantarjian HM, Koller C, Taher A.
    Cancer; 2008 Mar 01; 112(5):1089-95. PubMed ID: 18186499
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan 01; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec 01; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P, Rose C.
    Blood Rev; 2009 Dec 01; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [Abstract] [Full Text] [Related]

  • 9. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L.
    Leuk Res; 2007 Dec 01; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Consensus statement on iron overload in myelodysplastic syndromes.
    Bennett JM, MDS Foundation's Working Group on Transfusional Iron Overload.
    Am J Hematol; 2008 Nov 01; 83(11):858-61. PubMed ID: 18767130
    [Abstract] [Full Text] [Related]

  • 13. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L.
    Cancer; 2006 May 15; 106(10):2087-94. PubMed ID: 16607649
    [Abstract] [Full Text] [Related]

  • 14. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
    Mundle SD.
    Future Oncol; 2007 Aug 15; 3(4):397-403. PubMed ID: 17661714
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec 15; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H, SUZUKI T, OMORI T, MORI M, UEHARA E, HATANO K, UEDA M, MATSUYAMA T, TOSHIMA M, QZAKI K, NAGAI T, MUROI K, OZAWA K.
    Rinsho Ketsueki; 2009 Nov 15; 50(11):1626-9. PubMed ID: 20009438
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.